Clinical Trial Update: Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the combination of retinfanlimab with INCAGN02385 and INCAGN02390 as first-line therapy for PD-L1-positive recurrent/metastatic head …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• INCAGN02385 (LAG-3 inhibitor)
• INCAGN02390 (TIM-3 inhibitor)
• Retinfanlimab (retinfanlimab)

Snippet

Sponsor: Incyte Biosciences International Sàrl | Conditions: Head and Neck Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-03-27